RCGHX Mutual Fund

NAV$17.21

Fund Essentials - as of Mar 31, 2026

Net Assets
$1M
Expense Ratio
2.16%
Dividend Yield (Current)
-
Holdings
24
Inception Date
Feb 5, 2002
Fund Family
Virtus Investment Partners
Investment Style
••••••••••
Asset Class
••••••••••
Legal Structure
••••••••••
Dividend Frequency
Unspecified

Performance

YTD+0.35%
1 Year+12.78%
3 Year+1.39%
5 Year+7.77%
10 Year+15.08%

Asset Allocation

Stocks: 100.00%

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly & Co13.30%
MCKMckesson Corp5.57%
ABBVAbbvie Inc5.09%
VRTXNvaesrtex Pharmaceuticals Inc5.09%
MRKMerck & Company Inc5.05%
Top 10 Concentration: 55.84%Report Date: Mar 31, 2026
Download all 24 holdings for RCGHX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Unspecified
Latest Distribution
$7.49
-

Peer Comparison

Benchmark
••••••••••
Outperforming by ••••%
Ranked #••• of •,••• funds
This Mutual Fund
+••.••%
Peer Avg
+••.••%
Premium Feature
Sign in to unlock peer comparison, category rankings and more

RCGHX Mutual Fund Overview

RCGHX Mutual Fund (Virtus KAR Health Sciences Fund Class C) is managed by Virtus Investment Partners with $1.1M in net assets. RCGHX expense ratio is 2.16%, holding 24 positions across sectors including Health Care, Unknown, Consumer Staples. Inception date: 2002-02-05.

RCGHX performance shows a YTD return of 0.35%. The 1-year return is 12.78% and the 5-year return is 7.77%.

RCGHX top holdings include Eli Lilly & Co (13.3%), Mckesson Corp (5.6%), Abbvie Inc (5.1%), Nvaesrtex Pharmaceuticals Inc (5.1%), Merck & Company Inc (5.0%). View all RCGHX holdings, sector breakdown, or dividend history.

RCGHX can be compared against other funds using the overlap calculator or side-by-side comparison tool. RCGHX alternatives are available via the screener, along with tax-loss harvesting opportunities.